Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEAMERICAN:APHBNASDAQ:GANXCVE:MPHNASDAQ:VINC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPHBAmpliphi Biosciences$2.53+1.2%$0.00$0.15▼$1.37$84.70MN/A842,200 shs4,683 shsGANXGain Therapeutics$3.07-3.8%$4.01$2.00▼$5.65$49.80M0.43154,054 shs142,396 shsMPHMedicureC$1.02-6.4%C$1.14C$0.99▼C$1.80C$10.46M1.014,477 shs10,000 shsVINCVincerx Pharma$0.90-3.2%$4.09$0.61▼$9.37$19.20M1.11.25 million shs596,175 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGANXGain Therapeutics-3.76%-2.54%-19.21%-18.13%-40.27%MPHMedicure-6.42%-0.97%-15.00%-12.07%-22.14%VINCVincerx Pharma-3.58%-0.37%-82.49%-22.70%-29.95%Thousands of investors use this no cost solution | Do you? (Ad)In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage"MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AGANXGain Therapeutics3.1085 of 5 stars3.53.00.00.03.82.50.6MPHMedicureN/AN/AN/AN/AN/AN/AN/AN/AVINCVincerx Pharma1.5806 of 5 stars3.52.00.00.01.52.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPHBAmpliphi BiosciencesN/AN/AN/AN/AGANXGain Therapeutics3.00Buy$8.50176.87% UpsideMPHMedicureN/AN/AN/AN/AVINCVincerx Pharma3.00Buy$5.00457.60% UpsideCurrent Analyst RatingsLatest GANX, VINC, APHB, MPH, and ANIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2024GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/23/2024GANXGain TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.004/9/2024VINCVincerx PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight4/1/2024GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/1/2024VINCVincerx PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight3/27/2024GANXGain TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AGANXGain Therapeutics$50K995.91N/AN/A$0.97 per share3.16MPHMedicureC$22.94M0.46C$0.41 per share2.49C$2.10 per share0.49VINCVincerx PharmaN/AN/AN/AN/A$0.52 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPHBAmpliphi BiosciencesN/AN/A0.00∞N/AN/AN/AN/AN/AGANXGain Therapeutics-$22.27M-$1.71N/AN/AN/AN/A-193.03%-123.21%5/10/2024 (Estimated)MPHMedicureC$1.08MC$0.0911.33∞N/A4.71%5.04%2.49%5/24/2024 (Estimated)VINCVincerx Pharma-$40.16M-$1.89N/AN/AN/AN/A-187.73%-126.26%5/9/2024 (Estimated)Latest GANX, VINC, APHB, MPH, and ANIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/8/2024Q4 2023MPHMedicureN/A-C$0.14-C$0.14-C$0.14N/AC$5.07 million3/29/2024Q4 2023VINCVincerx PharmaN/A-$0.23-$0.23-$0.23N/AN/A3/26/2024Q4 2023GANXGain Therapeutics-$0.32-$0.29+$0.03-$0.29N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AMPHMedicureN/AN/AN/AN/AN/AVINCVincerx PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPHBAmpliphi BiosciencesN/AN/AN/AGANXGain Therapeutics0.043.593.59MPHMedicure2.862.281.29VINCVincerx PharmaN/A2.632.63OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPHBAmpliphi BiosciencesN/AGANXGain Therapeutics11.97%MPHMedicure23.10%VINCVincerx Pharma44.02%Insider OwnershipCompanyInsider OwnershipAPHBAmpliphi BiosciencesN/AGANXGain Therapeutics11.00%MPHMedicure26.99%VINCVincerx Pharma20.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPHBAmpliphi Biosciences3033.47 millionN/ANot OptionableGANXGain Therapeutics2816.22 million14.44 millionOptionableMPHMedicureN/A10.25 millionN/ANot OptionableVINCVincerx Pharma4121.41 million17.00 millionNot OptionableGANX, VINC, APHB, MPH, and ANIC HeadlinesSourceHeadlineVincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrantsglobenewswire.com - April 26 at 12:27 AMVincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrantsglobenewswire.com - April 25 at 4:01 PMVincerx Pharma, Inc. Common Stock (VINC)nasdaq.com - April 23 at 2:06 AMAACR: Biotechs emerge frostbitten from ‘nuclear winter,’ ready to show why they fought for survivalfiercebiotech.com - April 18 at 12:36 PMAnalyzing Revelation Biosciences (NASDAQ:REVB) and Vincerx Pharma (NASDAQ:VINC)americanbankingnews.com - April 16 at 2:40 AMAgendia’s BluePrint Included in German Oncology Group Guidelinesfinance.yahoo.com - April 12 at 9:45 AMVaccines, Next-Gen Approaches Target the Toughest Cancers: AACRbiospace.com - April 12 at 9:45 AMThe Rise of Zyn: The Oral Nicotine Product Going Viralfinance.yahoo.com - April 10 at 4:08 PMVincerx Pharma Inc (VINC) Gets a Buy from Leerink Partnersmarkets.businessinsider.com - April 10 at 9:44 AMVincerx (VINC) Tumbles on Results From Cancer Therapy Studyzacks.com - April 9 at 2:36 PMACOR, HUBC and DATS among pre-market losersmsn.com - April 9 at 9:19 AMVincerx in selloff after early-stage data for cancer therapymsn.com - April 9 at 9:19 AMCantor Fitzgerald Reaffirms Overweight Rating for Vincerx Pharma (NASDAQ:VINC)marketbeat.com - April 9 at 8:49 AMWhy Is Vincerx Pharma (VINC) Stock Down 64% Today?investorplace.com - April 9 at 8:40 AMVincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024globenewswire.com - April 8 at 4:30 PMFY2024 EPS Estimates for Vincerx Pharma, Inc. Raised by Analyst (NASDAQ:VINC)marketbeat.com - April 4 at 9:13 AMQ1 2024 EPS Estimates for Vincerx Pharma, Inc. (NASDAQ:VINC) Boosted by Leerink Partnrsmarketbeat.com - April 3 at 6:00 AMVINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023investorplace.com - April 2 at 8:06 AMVincerx Pharma, Inc.: Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updatefinanznachrichten.de - April 1 at 4:30 PMVincerx Pharma (NASDAQ:VINC) Receives Overweight Rating from Cantor Fitzgeraldmarketbeat.com - April 1 at 12:23 PMVincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024finance.yahoo.com - April 1 at 10:47 AMVincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close Lookfinance.yahoo.com - March 29 at 8:49 PMVincerx Pharma Cuts Funding-Sufficiency View to 3Q From Late 2024marketwatch.com - March 29 at 3:48 PMVincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updateglobenewswire.com - March 29 at 3:20 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Global benchmarks mostly climb despite worries about US economyApril 26, 2024 3:21 AMView Stock market today: Global benchmarks mostly climb despite worries about US economyFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeIntuitive Surgical Leads the Robotic Surgery MovementApril 22, 2024 6:10 AMView Intuitive Surgical Leads the Robotic Surgery MovementAll Headlines Company DescriptionsAmpliphi BiosciencesNYSEAMERICAN:APHBAmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.Gain TherapeuticsNASDAQ:GANXGain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies. The company's platform is enhanced with new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering chemical spaces of approximately 50 billion compounds. It deploys its platform by accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders, including neurodegenerative diseases, rare genetic disorders, and oncology. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.MedicureCVE:MPHMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.Vincerx PharmaNASDAQ:VINCVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.